debt_leverage_profile
Minimal long-term debt; primarily equity-financed biotech with ~$300M cash runway; 20% rate rise has negligible P&L impact
Inferred
Agent_Inference
interest_rate_sensitivity
Low sensitivity; debt-light balance sheet means rate increases marginally affect cash yield on holdings, not interest expense
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Contract manufacturing organizations (CMOs) in US/Europe; API active ingredient sourcing from limited CDMO suppliers creates concentration risk
Inferred
Agent_Inference
international_expansion_readiness
Minimal direct international revenue; partnership royalties from Zymeworks/others limit direct FX exposure; sovereign devaluation risk is low
Inferred
Agent_Inference
geographic_footprint
Predominantly US-based revenue; ex-US exposure via licensing deals limits direct currency devaluation risk to royalty payment translations
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CMO dependency for MARGENZA biologics manufacturing represents critical non-substitutable input; switching cost is 12-18 months minimum
Inferred
Agent_Inference
business_model_type_primary
Cloud infrastructure termination would disrupt internal R&D data systems but not revenue generation; clinical/commercial ops are not cloud-delivery dependent
Inferred
Agent_Inference
business_model_type_secondary
Hybrid: internal biotech R&D platform combined with external licensing/partnership revenue model; not SaaS or cloud-critical
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; proprietary Fc-optimization (Fc-optimization DART platform) is internal IP, not dependent on third-party APIs
Inferred
Agent_Inference
howey_test_risk_index
Revenue model (drug sales + licensing) does not constitute an investment contract; Howey Test is not applicable to pharmaceutical commercial operations
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Clinical trial patient data subject to GDPR for EU trials and CCPA for California subjects; moderate compliance exposure requiring ongoing DPA agreements
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche oncology/autoimmune biologics market with multiple competitors; no dominant market position in any therapeutic category
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional: MARGENZA product sales (~60%) plus milestone/royalty payments (~40%); minimal recurring subscription-type revenue
Inferred
Agent_Inference
monetization_vector
Drug product sales (MARGENZA) + collaboration milestone payments + royalties from licensing proprietary bispecific antibody platform
Inferred
Agent_Inference
pricing_architecture
Oncology biologics pricing at ~$3,000-5,000/dose for MARGENZA; subject to payer/formulary pressure; biosimilar threat is medium-term risk
Inferred
Agent_Inference
pricing_power_rating
Moderate; oncology niche provides pricing power but payer pushback and competing HER2 therapies (Enhertu) cap upside; rating ~5/10
Inferred
Agent_Inference
target_gross_margin_bracket
Pharmaceutical gross margins target 70-80%; currently pressured by manufacturing costs and low MARGENZA volume; likely 60-70% at current scale
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage; prescription drug sales are transactional with no meaningful parallel access mechanism; churn risk is payer formulary exclusion
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth potential; R&D platform scalable without proportional headcount increase; commercial scaling requires modest sales force expansion
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of pipeline advancement is primarily clinical trial spend (CRO fees, patient costs), not headcount-linear; platform economics are favorable
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics improve via existing oncologist relationships; key constraint is label expansion and competitive formulary positioning
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; value derived from proprietary IP and clinical outcomes data, not user-base growth dynamics
Inferred
Agent_Inference
asset_efficiency_ratio
-29.3% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 2 recession resistance; oncology treatments are medically necessary but reimbursement pressure and clinical trial enrollment can slow in downturns
Inferred
Agent_Inference
customer_segment_primary
Oncologists and hospital systems prescribing MARGENZA for HER2-positive metastatic breast cancer; concentrated in academic medical centers
Inferred
Agent_Inference
customer_segment_secondary
Large pharma/biotech collaboration partners (e.g., Incyte, Janssen) licensing DART bispecific platform for pipeline development
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
1.3% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001125345
High
SEC-EDGAR
ticker
MGNX
High
SEC-EDGAR